The Amplatzer Amulet left atrial appendage (LAA) occluder was at least as good as the first-generation Watchman in keeping strokes down, according to the randomized IDE trial that helped convince FDA ...

Beyond the periprocedural period, use of the Watchman device for left atrial appendage (LAA) closure reduces the risk of major bleeding compared with chronic warfarin therapy, according to an analysis ...

Operators come to grips with LAA contractility in observational study ...

Initial results from more than 800 atrial fibrillation patients presented at Transcatheter Cardiovascular Therapeutics 2016 indicate the AMPLATZER™ Amulet™ LAA Occluder is a safe alternative to ...

Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Left Atrial Appendix, (LAA), occluder. The device ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...

Percutaneous left atrial appendage (LAA) closure with the Watchman device was cost-saving in the long-term, even after accounting for the uptick in stroke risk observed in one trial, researchers ...